ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer
ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer
复制标题
DOI：
10.1016/j.lungcan.2007.08.025
复制
发表时间：
2008-03-01
期刊：
影响因子：
5.3
通讯作者：
Date, Hiroshi
中科院分区：
文献类型：
--
作者：
Fujii, Tetsuya;Toyooka, Shinichi;Date, Hiroshi
切除修复交叉互补组 1 (ERCC1) 和 BRCA1 已被确定为非小细胞患者临床结果的预测因子。采用基于顺铂的化疗治疗肺癌（NSCLC）。在本研究中，我们回顾性研究了35例治疗前获得的转移性纵隔淋巴结患者的ERCC1和BRCA1蛋白表达水平。这些患者已被纳入我们的顺铂和伊立替康新辅助化疗（15 名患者）或顺铂和多西他赛放化疗加同步胸部放疗（20 名患者）的研究。检测ERCC1或BRCA1蛋白表达与患者临床结局的关系。新辅助化疗组ERCC1阴性肿瘤患者的放射学有效率和病理有效率均显着高于阳性肿瘤患者（放射有效率100% vs 42.8%，P=0.013；病理有效率100% vs 47.1%， P=0.038），但在新辅助放化疗组中未观察到相关性。关于生存期，新辅助化疗组和放化疗组中ERCC1阴性和阳性肿瘤患者的总生存期或无病生存期均未观察到显着差异。 总之，我们发现ERCC1阴性蛋白状态与肿瘤对顺铂和伊立替康新辅助化疗的反应性显着相关，但这种状态并不是NSCLC患者基于顺铂的新辅助治疗的明确预后预测因子。需要进一步的研究来阐明分子预测因子对于 NSCLC 患者定制治疗的价值。 (C) 2007 Elsevier Ireland Ltd. 保留所有权利。
The excision repair cross-complementation group 1 (ERCC1) and BRCA1 have been identified as predictors of clinical outcomes among patients with non-small-cell. lung cancer (NSCLC) treated with cisplatin-based chemotherapy. In this study, we immunohistochemically examined the ERCC1 and BRCA1 protein expression levels in 35 patients with metastatic mediastinal lymph nodes obtained prior to treatment as retrospective study. These patients had been enrolled in our studies on neoadjuvant chemotherapy with cisplatin and irinotecan (15 patients) or chemoradiotherapy with cisplatin and docetaxel plus concurrent thoracic radiation (20 patients). The relations between the ERCC1 or BRCA1 protein expression and the clinical outcomes of the patients were then examined.The rates of radiological response and pathological effectiveness were significantly higher among patients with ERCC1-negative tumors, compared with those with positive tumors in the neoadjuvant chemotherapy group (radiological response rates; 100% vs. 42.8%, P=0.013; pathological effectiveness; 100% vs. 47.1%, P=0.038), but no associations were observed in the neoadjuvant chemoradiotherapy group. Regarding survival, no significant differences in overall survival or disease-free survival were observed between patients with ERCC1-negative and positive tumors in both the neoadjuvant chemotherapy and chemoradiotherapy groups.In summary, we showed that a ERCC1-negative protein status was significantly related to tumor responsiveness to neoadjuvant chemotherapy with cisplatin and irinotecan, but such a status was not a clear prognostic predictor to cisplatin-based neoadjuvant therapy in NSCLC patients. Further study is needed to clarify the value of molecular predictors for customizing therapy for patients with NSCLC. (C) 2007 Elsevier Ireland Ltd. All rights reserved.